Cambridge Respiratory Innovations Limited (CRiL) has signed a collaboration agreement with Linde AG that covers clinical and commercial validation during development of its N-Tidal B personal respiratory monitor and potential rights to commercialise it for specific indications.
As part of this agreement, CRiL will also establish a Commercial Advisory Board (CAB). The primary objective of CRiL’s CAB is to enlist the expertise of internationally respected leaders in cardio-respiratory health to refine and optimise the commercial road map for CRiL’s innovative N-Tidal technology. Representing Linde Healthcare, a global business unit of The Linde Group, will be Urmi Prasad Richardson, Global Head of Healthcare in the Centre of Excellence.
Jeremy Walsh, CRiL’s CEO, commented, “The formation of the CAB, with senior representation from major partners like Linde, marks a significant milestone in the development of our company. We are delighted that Urmi will be advising our company. She has a wealth of international healthcare experience in diagnostics, therapeutics and services which will be extremely valuable to us, especially as Linde Healthcare is the established global leader in home therapy of COPD and other chronic respiratory conditions.”
CRiL also announced that the CAB will include Dr. Edward Philpott, Global Strategy Drug Development & Head, Respiratory Centre of Excellence for IQVIA, a leading global provider of information, innovative technology solutions and contract research services to the healthcare industry formed through the merger of IMS and Quintiles. The board will be chaired by Cliff Murphy, Managing Partner of ConAlliance UK, which has been providing strategic development consultancy to CRiL’s management team since 2016.
... to continue reading you must be subscribed
